EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading ​false or misleading information about EyePoint and its ‌lead experimental eye drug.

These are some of the stocks posting the largest moves midday.

Eyepoint and Rentschler Biopharma are among 38 companies sharing nearly $40 million in Massachusetts life sciences tax incentives.

Pomerantz LLP investigates potential securities fraud by EyePoint, Inc., urging its investors to take legal action following a significant stock drop.

EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading ​false or misleading information about EyePoint and its ‌lead experimental eye drug.

EyePoint ‌said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision from causes unrelated to the targeted disease, sending its shares tumbling more than 70% on Monday.

EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche's Vabysmo in the eye disease market.

4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.

Using AI to find stock market opportunities.

EyePoint (Nasdaq:EYPT) reported topline results from LUGANO, the first pivotal Phase 3 trial of DURAVYU™ 2.7mg in wet AMD versus on‑label 2 mg aflibercept. The primary endpoint (BCVA change) was not achieved in the full dataset, affected by a 4% asymmetric cohort (9/211 DURAVYU patients) with ≥15‑letter vision loss unrelated to wet AMD; no such cases occurred in the aflibercept arm. An ad hoc analysis excluding this cohort showed non‑inferiority for DURAVYU (nominal p=0.0096).Key secondary endpoints favored DURAVYU, including a 42% reduction in treatment burden (two fewer injections on average; p<0.0001), high supplement‑free rates (76% to Week 32; 54% to Week 56; 79% with 0–1 supplement to Week 56), non‑inferior BCVA in supplement‑free patients (p=0.0035), strong anatomic control with a 4‑micron CST difference at Week 56 (3 microns in supplement‑free eyes), and a favorable safety profile with repeat dosing. EyePoint expects topline data from the second pivotal wet AMD trial, LUCIA, in Q4 2026 and is planning a potential FDA NDA submission for DURAVYU in 1H 2027, pending those results. Phase 3 DME trials COMO and CAPRI have fully enrolled, with topline data anticipated in Q4 2027.

25 articles from 8 sources covering $435M+ in M&A deals, FDA regulatory moves including a generative AI device framework, clinical setbacks at Regeneron and EyePoint, and a bullish CDMO outlook driven by recovering biotech funds.

EyePoint hit a 52-week low of $3.95 after its Phase 3 LUGANO trial missed its primary goal. Stellantis fell to a 12-year low of $5.10 after recalling 955,000 vehicles over a rear-view camera software issue. Enovix fell to a record low of $3.52 after CEO Raj Talluri resigned. EyePoint Inc. (EYPT), Stellantis N.V. (STLA) and Enovix Corp. (ENVX) stocks tumbled to 52-week lows on Monday, as investors reacted to a failed clinical endpoint, a large-scale vehicle recall and an unexpected leadership change.

ORLANDO — In this video, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses preclinical data on vorolanib presented at Eyecelerator@AAO. “We’ve always known that vorolanib was a potent inhibitor of all the VEGF receptors,” Duker said. “What we’ve now discovered is we also have an anti-inflammatory component to vorolanib.” Duker explained that “with this essentially bispecific approach of blocking both VEGF and inflammation, we are especially confident in the results of our clinical trial.”

This is a a trinocular 3.5X-180X zoom stereo boom microscope with 54-LED ring light. The microscope comes with a trinocular head with 30mm SUPER widefield high-eyepoint eyepieces and single-arm heavy-...

EyePoint Pharmaceuticals is attempting to salvage its lead drug candidate, DURAVYU, by characterizing a failed Phase III trial as a statistical anomaly. The company is now focusing on secondary endpoints and a second upcoming study. The LUGANO trial, which evaluated the drug for wet age-related macu

Pomerantz LLP is conducting an investigation on behalf of EyePoint, Inc. investors. Concerns arise over potential securities fraud linked to a recent clinical trial announcement.

This is a binocular 7X-45X zoom stereo microscope that gives crystal clear sharp images. It comes with a binocular head with 30mm super widefield, high-eyepoint 10X eyepieces and a double-arm heavy-duty boom stand. The 45 degree inclined binocular and high-eyepoint design ensures an easy observation, especially for eyeglass wearers. The rubber eye-guards provide further comfort. The double-arm boom stand allows you to turn the microscope head around three different axes (x, y, and z), allowing you to point the microscope head toward to ANY direction. This microscope offers high resolution, super widefield of view, 6.5:1 magnifying zoom range and 4" (100mm) working distance. It is an ideal instrument for research labs, gemologists, engravers, collectors and anyone in semiconductor and/or electronic industry. This stereo zoom microscope is made by the same technicians and on the same production line as optical instruments for Leica, Zeiss, Nikon and Olympus. It is brand new in factory box. Its retail value is $1600.

ORLANDO — In this video from the American Academy of Ophthalmology meeting, Arshad M. Khanani, MD, MA, FASRS, discusses developments in the treatment of neovascular age-related macular degeneration. Khanani delved into tyrosine kinase inhibitors, including the SOL-1 and SOL-R trials evaluating OTX-TKI (axitinib implant, Ocular Therapeutix) in neovascular AMD and the LUCIA and LUGANO studies of vorolanib (EyePoint Pharmaceuticals), which is designed to be delivered every 6 months to treat neovascular AMD. Khanani also touched on gene therapy programs in development: ABBV-RGX-314 (AbbVie,